NeuroOne Promotes Emily Johns to Expanded Chief Administrative Officer Role

NeuroOne Medical Technologies Corporation has announced the promotion of Emily Johns to the expanded role of Chief Administrative Officer and General Counsel. Johns, who joined NeuroOne earlier this year as General Counsel, will continue to lead the company's legal strategy while taking on additional responsibilities overseeing all human resources, compliance, security, and risk areas of the organization. This strategic move comes as NeuroOne focuses on scaling its business and expanding the reach of its medical technologies for neurological disorders.

Dave Rosa, President and CEO of NeuroOne, emphasized Johns' significant contributions since joining the company, stating that she has made impactful contributions to the organization and the future growth of the business. The promotion reflects the company's confidence in Johns' ability to strengthen operations and infrastructure during a critical growth phase. NeuroOne is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders.

Johns brings substantial experience to her expanded role, having most recently served as a partner at Honigman LLP, where she represented numerous companies in the life sciences industry. Her background includes representing NeuroOne on all transactional work since 2017, providing her with deep institutional knowledge of the company's operations and strategic direction. Prior to her time at Honigman, Johns began her career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and M&A transactions. Her educational background includes a J.D. from UCLA School of Law and a bachelor's degree from the University of Michigan.

The promotion signals NeuroOne's commitment to strengthening its administrative infrastructure as the company pursues broader commercialization of its medical technologies. Johns expressed honor in stepping into the expanded role and emphasized her commitment to building on the strong foundation the team has created. She noted her focus on strengthening operations and infrastructure to help bring NeuroOne's life-changing technologies to more people. The company's technology portfolio aims to improve patient outcomes while reducing procedural costs, with potential future applications in areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information about the company's technologies and developments, visit https://www.nmtc1.com.

This leadership transition occurs as NeuroOne continues to advance its mission of improving surgical care options and outcomes for patients suffering from neurological disorders. The expanded role for Johns underscores the importance of robust administrative, legal, and compliance frameworks in supporting the company's growth trajectory and technological advancements in the competitive medical technology landscape. The company's focus on minimally invasive solutions positions it at the forefront of innovation in neurological treatment options, with the potential to significantly impact patient care and treatment accessibility across multiple neurological conditions.